Total assets $ 8,259,681 $ 22,596,371
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Current liabilities
Accounts payable $ 404,008 $ 581,749
Accrued expenses 547,119 429,627
Accrued royalties 123,852 146,016
Accrued payroll, bonus
and related liabilities 595,276 195,791
Deferred revenue 1,628,325 3,910,301
Total current liabilities 3,298,580 5,263,484
Notes payable to stockholders 716,854 --
Accrued interest on notes
payable to stockholders 329,036 --
Accrued dividends 6,097,579 --
Deferred revenue,
net of current portion 3,320,000 1,603,186
Total liabilities 13,762,049 6,866,670
Commitments and contingencies
Stockholders' (deficit) equity
Series B Convertible Preferred Stock,
$0.01 par value; 1,038,048 and 0 issued
and outstanding (liquidation preference
of $9 per share, or $9,342,432 plus
accrued but unpaid dividends) at
December 31, 2006 and September 30, 2007,
respectively 10,380 --
Series A Junior Convertible Preferred Stock,
$0.01 par value; 500,000 and 0 issued and
outstanding (liquidation preference of $5
per share, or $2,500,000) at December 31,
2006 and September 30, 2007, respectively 5,000 --
Common stock, $0.01 par value; 20,000,000
and 50,000,000 shares authorized; 2,726,320
and 10,239,27
'/>"/>
| SOURCE Response Genetics, Inc. Copyright©2007 PR Newswire. All rights reserved |